anatomy of head and neck muscles figure  6 1

... stage of primary) Subsite Percentage of metastases reported in prophylactically treated necks Oral cavity68, 86, 14 4 ,14 5 ,15 3 ,15 9- 16 7 >20% Glottic68 ,1 46 0 -15 % Supraglottic147 -14 9 ,15 1 ,15 4 -15 7 8-30% ... palliation of particular symptoms, taking local expertise into consideration 31 diagnosis and management of head and neck cancer 11 Laryngeal cancer 11 .1 EARLY LARYNGEAL CAncer (Stage I and II) 11 .1. 1 ... glottic and supraglottic) and clinically N0 neck. 1 46, 16 7 ,407, 413 Nodal metastases may be bilateral in 27% of patients .15 8 Occult disease is most common at neck nodal levels II, III and IV .15 1 ,15 2,402...

Ngày tải lên: 14/02/2014, 22:20

... Guide to NECK DISSECTION CLASSIFICATION AND TNM STAGING OF HEAD AND NECK CANCER Committee for Head and Neck Surgery and Oncology American Academy of Otolaryngology– Head and Neck Surgery Neck Dissection ... of: Pocket guide to neck dissection classification and TNM staging of head and neck cancer / Committee for Neck Dissection Classification, American Head and Neck Society [and] Committee for Head ... Head and Neck Surgery and Oncology, American Academy of Otolaryngology— Head and Neck Surgery ; edited by K Thomas Robbins 2nd ed 20 01 Includes bibliographical references ISBN 978 -1- 567 72 -11 7-1...

Ngày tải lên: 15/03/2014, 00:20

... mucosal surface of the lip DIAGRAM OF THE HEAD AND NECK Oral cavity Oropharynx Larynx Hypopharynx ALL HEAD AND NECK CANCERS DIAGRAM OF THE LYMPH NODES LEVELS IN THE NECK I II III VI IV V NECK DISSECTION ... within two weeks of urgent referral DIAGNOSIS AND STAGING D Fine needle aspiration cytology should be used in the investigation of head and neck masses D All patients with head and neck cancer should ... areas of metastatic disease in patients with head and neck cancer should include: number of involved nodes level of involved nodes extracapsular spread of tumour type of nodal dissection size of...

Ngày tải lên: 15/03/2014, 01:20

... 0 .11 9 90.0% IVb 47 57.2% 0-2 66 .7% 3-4 51 60 .5% 12 50.0% 45 57.3% 60 00 cGy 20 55.0% > 60 00 cGy 37 64 .5% never 11 63 .6% yes 46 60 .6% 48 66 .7% 60 .1% 0 . 61 4 66 .7% 60 .0% 0 .67 9 never 20 70.0% 0 .63 8 ... (42 .1% ) 11 (45.8%) 13 (54.2%) oropharynx 21 ( 36. 8%) 10 (47 .6% ) 11 (52.4%) 1. 58 (0.35, 7.07) 0.549 hypopharynx/Larynx 12 ( 21. 1%) 10 (83.3%) ( 16 . 7%) 0.0 96 (0.007, 1. 33) 0.0 81 Stage IVa 10 (17 .5%) ... 20 06, 24(Suppl):284s, abstract Chiu et al Journal of Translational Medicine 2 011 , 9: 31 http://www.translational-medicine.com/content/9 /1/ 31 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26...

Ngày tải lên: 18/06/2014, 19:20

... 0 .11 9 90.0% IVb 47 57.2% 0-2 66 .7% 3-4 51 60 .5% 12 50.0% 45 57.3% 60 00 cGy 20 55.0% > 60 00 cGy 37 64 .5% never 11 63 .6% yes 46 60 .6% 48 66 .7% 60 .1% 0 . 61 4 66 .7% 60 .0% 0 .67 9 never 20 70.0% 0 .63 8 ... (42 .1% ) 11 (45.8%) 13 (54.2%) oropharynx 21 ( 36. 8%) 10 (47 .6% ) 11 (52.4%) 1. 58 (0.35, 7.07) 0.549 hypopharynx/Larynx 12 ( 21. 1%) 10 (83.3%) ( 16 . 7%) 0.0 96 (0.007, 1. 33) 0.0 81 Stage IVa 10 (17 .5%) ... 20 06, 24(Suppl):284s, abstract Chiu et al Journal of Translational Medicine 2 011 , 9: 31 http://www.translational-medicine.com/content/9 /1/ 31 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26...

Ngày tải lên: 20/06/2014, 03:20

... [PMID: 16 4 67544] Brockstein B, Vokes EE: Concurrent chemoradiotherapy for head and neck cancer Semin Oncol 31: 7 86, 2004 [PMID: 15 5998 56] Cohen EE et al: The expanding role of systemic therapy in head ... advanced head and neck cancer N Engl J Med 350 :19 45, 2004 [PMID: 15 128894] Bonner JA et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354: 567 , 20 06 [PMID: ... comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21: 92, 2003 [PMID: 12 5 0 61 76] Bernier...

Ngày tải lên: 07/07/2014, 01:20

... Head and Neck: A Single Institution Matched Case-Control Study Am J Clin Oncol 2 011 , 34: 16 5 -72 doi :10 .11 86/ 17 48- 717 X -6- 98 Cite this article as: Yamazaki et al.: Reirradiation of head and neck cancer ... Yamazaki et al Radiation Oncology 2 011 , 6: 98 http://www.ro-journal.com/content /6/ 1/ 98 Page of 10 Received: May 2 011 Accepted: 21 August 2 011 Published: 21 August 2 011 20 References Vokes EE, Weichselbaum ... report of RTOG 9 61 0, a multiinstitutional trial ofreirradiation and chemotherapy for unresectable 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 recurrent squamous cell carcinoma of the head and neck...

Ngày tải lên: 09/08/2014, 09:21

... PET/CT-GTV 17 .7 65 .9 16 . 1 52.5 5.4 45.5 8.7 35.3 6. 3 17 .4 2 .1 9.8 37.0 6. 0 28.9 6. 5 13 .4 1. 3 17 .8 40.8 7 .1 19.5 30.3 49.0 22.2 34 .1 1.7 46. 3 12 .1 20 .1 3.5 8.0 4.5 1. 7 57.8 2 .6 11 .2 17 .3 4.7 4.0 15 .2 ... 11 .2 17 .3 4.7 4.0 15 .2 34.7 8.9 6. 5 36. 5 78.7 25 .1 60 .2 5.4 64 .2 13 .5 36. 1 6. 4 17 .8 5.3 9.8 60 .3 6. 2 29.4 19 .8 13 .9 5.0 20.3 61 .8 11 .9 19 .5 Discussion The use of FDG-PET/CT prior to treatment ... http://www.ro-journal.com/content/3 /1/ 29 Table 3: Volumes (cc) identified by CT and PET in every single case Patients Subsites CT-GTV 10 11 12 13 14 15 16 17 18 19 20 21 22 Nasopharynx Oral Cavity Oral...

Ngày tải lên: 09/08/2014, 09:22

... Total 21 45.0 14 .0 30.0 66 ,0 15 30.0 9.3 25.0 50.0 21 21. 0 10 .3 7.0 42.0 21 65 .0 11 .6 46 10 5.0 21 53 .1 13.8 53 .1 86. 1 21 31. 0 17 .9 13 .0 91. 0 21 35.4 10 .9 29,5 59.0 21 111 .2 22.2 62 .2 1 46. 8 Legend ... Local control % P* 15 56. 7 73.3 0.3330 10 50.0 50.0 66 .7 0.3485 14 71. 5 52.8 0.8920 13 63 .5 53.8 0.94 36 16 60.0 50.0 0.4 365 12 6 50.0 66 .7 33.3 0.8 814 12 50.0 55.5 0.8 966 13 11 84 .6 0.0007 tion (primarily ... Previous Chemotherapy Yes No Total n pacients % 15 71. 4 28 .6 16 76. 2 23.8 10 4.8 19 .0 47 .6 28 .6 12 57 .1 28 .6 14 .3 15 71. 4 28 .6 01 20 4.8 95.2 21 100 median 53.5 Three-dimensional planning CT image...

Ngày tải lên: 09/08/2014, 10:21

... 13 (18 .6% ) 1( 1.9%) 26 11 Lip Sarcomas 8(2 .6% ) 1( 1.4%) Mandible 43 (13 .9%) 26( 37 .1% ) 16 ( 30.2%) 85 Maxilla 63 (20.3%) 22( 31. 4%) 20(37.7%) 10 5 Salivary glands 57 (18 .4%) 2(2.9%) 1( 1.9%) 60 Face 20 (6. 5%) ... TOTAL MALE 5 86 (67 .0%) 65 ( 61 .3%) 12 9 ( 61 .7%) (50%) 7 81 FEMALE 288 (32.9%) 41 (38.7%) 80 (38.3%) (50%) 410 MISSING (0 .1% ) TOTAL 875 (10 0%) 1 06 (10 0%) 209 (10 0%) (10 0%) 11 92 Adisa et al Head & Face ... 14 (13 .2%) 3(2.8%) 1 06( 10 0%) 1( 50%) 1( 50%) 0 2 (10 0%) 85(7 .1% ) Sarcomas 14 4 (12 .1% ) 330(27.7%) 434( 36. 5%) 19 7( 16 . 6%) 11 90 (10 0%) Neuroendocrine tumours TOTAL *Two ages missing lymphomas (20.4%) and sarcomas...

Ngày tải lên: 11/08/2014, 20:21

... 2.5 IL6 0.0 * 2.0 1. 5 * * * * * * 0.0 1. 5 IL1A 1. 0 IL1B 1. 0 1. 5 * * 1. 0 0.5 * * * * 0.5 0.5 * 0.0 1. 5 0.0 1. 5 IL1R2 0.0 1. 5 IL1RN 1. 0 1. 0 * 0.0 1. 5 CSF2 1. 0 * * 0.5 * * 0.5 * * * 0.0 0.0 1. 5 IGFBP3 ... PLCG2↑, PRKX↓ W 4.4 × 10 -2 IKBKE↑, IL1A↓, IL1R2↓, IL1RN↓, IL6↑, IL8↑ M 1. 7 × 10 -2 IL1A↓, IL1B↓, IL1R2↓, IL6↑, IL6ST↓, TNFRSF1A↓, MAP4K4↓, LBP↑ W 4.8 × 10 -2 DUSP10↑, IL1A↓, IL1R2↓, IL1RN↓, MAPKAPK3↓, ... 8 .1 × 10 -3 ANGPT1↓, CXCL14↓, EFNB1↓, EPHB2↑, EPHB4↓, ITGA2↓, GNA15↓, GNAI2↓, GNB1↓, GNG12↓, IL8↑, PGF↓ M 2.3 × 10 -3 AKT1↓, ANGPT1↓, AXIN1↑, CXCL14↑, EFNB1↓, GNA15↓, GNAI2↓, GNB2↓, GNB4↓, GNG12↓,...

Ngày tải lên: 14/08/2014, 08:20

... microenvironments Chem Rev., 10 8, 17 87 17 96 15 2 Vacanti, C.A (20 06) History of tissue 15 3 15 4 15 5 1 56 15 7 15 8 15 9 16 0 16 1 16 2 engineering and a glimpse into its future Tissue Eng., 12 , 11 37 11 42 Griffith, C.K., ... Li, J., Chen, J., and Kirsner, R (2007) Pathophysiology of acute wound healing Clin Dermatol., 25, 9 18 11 5 Ravanti, L and Kähäri, V.M (2000) 1 16 11 7 11 8 11 9 12 0 12 1 12 2 12 3 12 4 Matrix metalloproteinases ... A., Neuenschwander, P., and 1 06 10 7 10 8 10 9 11 0 11 1 11 2 11 3 11 4 Suter, U.W (19 98) Tissue-compatible multiblock copolymers for medical applications, controllable in degradation rate and mechanical...

Ngày tải lên: 25/10/2013, 08:20

... et al Mycobacterial infections of the head and neck Otolaryngol Head Neck Surg 19 93 ;10 9(3 pt 1) :427-433 62 62 Am J Clin Pathol 2007 ;12 8:35 -67 DOI: 10 .13 09/6BBT12WGNK77N4EH 40 Bayazit YA, Bayazit ... Laryngoscope 19 94 ;10 4 :10 74 -10 79 Am J Clin Pathol 2007 ;12 8:35 -67 © American Society for Clinical Pathology 63 DOI: 10 .13 09/6BBT12WGNK77N4EH 63 63 Montone / HEAD AND NECK INFECTIONS 10 8 Corey JP ... problems in diagnosis and treatment Laryngoscope 19 91; 1 01: 815 -820 1 06 Bent JP, Kuhn FA Diagnosis of allergic fungal sinusitis Otolaryngol Head Neck Surg 19 94 ;11 1:580-587 10 7 Cody DT, Neel HB,...

Ngày tải lên: 19/02/2014, 08:20

... Engl J Med 20 01, 345 :18 90 -19 00 Takikita et al Journal of Translational Medicine 2 011 , 9 :1 26 http://www.translational-medicine.com/content/9 /1/ 1 26 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Olayioye ... Median 61 .0 61 .0 Range 23 - 88 20 - 95 0. 866 60 .0 63 .1 20 - 95 41 - 81 0 .14 0 61 61 24 - 95 20 - 88 66 (22.3) 227 (77.7) 22 (23.2) 0.972 73 ( 76. 8) Gender Male 217 (74.3) 75 (25.7) 66 (69 .5) 29 ... (68 .3) 18 (20.2) 73 ( 31. 7) 49 (83 .1) 10 ( 16 . 9) No 265 (73.0) 98 (27.0) Yes 13 ( 81. 2) (18 .8) Female Primary tumor sites Grade 0.355 13 (13 .7) 16 4 (89 .6) 19 (10 .4) 39 ( 21. 3) 14 4 (78.7) 14 7 (93 .6) 10 ...

Ngày tải lên: 18/06/2014, 22:20

... Engl J Med 20 01, 345 :18 90 -19 00 Takikita et al Journal of Translational Medicine 2 011 , 9 :1 26 http://www.translational-medicine.com/content/9 /1/ 1 26 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Olayioye ... Median 61 .0 61 .0 Range 23 - 88 20 - 95 0. 866 60 .0 63 .1 20 - 95 41 - 81 0 .14 0 61 61 24 - 95 20 - 88 66 (22.3) 227 (77.7) 22 (23.2) 0.972 73 ( 76. 8) Gender Male 217 (74.3) 75 (25.7) 66 (69 .5) 29 ... (68 .3) 18 (20.2) 73 ( 31. 7) 49 (83 .1) 10 ( 16 . 9) No 265 (73.0) 98 (27.0) Yes 13 ( 81. 2) (18 .8) Female Primary tumor sites Grade 0.355 13 (13 .7) 16 4 (89 .6) 19 (10 .4) 39 ( 21. 3) 14 4 (78.7) 14 7 (93 .6) 10 ...

Ngày tải lên: 20/06/2014, 04:20

... [8] [9] [10 ] [11 ] [12 ] [13 ] [14 ] [15 ] [ 16 ] [17 ] [18 ] [19 ] [20] [ 21] [22] [23] therapy of voice, speech, and language disorders,” Logopedics Phoniatrics Vocology, vol 34, no 2, pp 91 96, 2009 G Van ... 30 20 WR mean ± standard deviation in % 50 ± 19 48 ± 14 76 ± WR min.; max in % 8; 82 17 ; 74 60 ; 91 10 0-gram 1- gram 2-gram 3-gram Figure 1: Effect of the language model context on the recognition ... Figures and 4) Discussion During and after therapy of malignant diseases of the head and neck, communication skills are of special interest Until now, no objective method with low effort and costs...

Ngày tải lên: 21/06/2014, 20:20

... 1 06 1 06 10 7 10 7 10 7 10 8 10 9 10 9 10 9 10 9 10 9 10 9 10 9 10 9 11 0 11 0 11 2 11 2 11 3 11 4 11 4 11 5 1 16 11 7 11 7 11 7 11 8 11 8 11 8 4.4.3 .6 Calcifying Odontogenic ... 8 11 1. 3.4.3 1. 3.4.4 1. 3.4.5 1. 3.5 1. 3.5 .1 1.3.5.2 1. 3.5.3 1. 3.5.4 1. 3 .6 1. 3 .6. 1 1.3 .6. 2 1. 3 .6. 3 1. 3 .6. 4 1. 3.7 1. 3.7 .1 1.3.7.2 1. 3.7.3 1. 3.8 1. 3.8 .1 1.3.8.2 1. 3.8.3 1. 3.8.4 1. 3.9 1. 3.9 .1 1.3.9.2 ... 13 7 13 7 5 .14 .1 5 .14 .2 14 0 14 0 14 1 14 2 14 3 14 3 14 4 14 4 14 4 14 4 14 4 14 4 1 46 14 7 14 8 5 .14 .3 5 .15 5. 16 15 7 15 8 15 8 15 8 15 9 15 9 16 2 16 2 ...

Ngày tải lên: 29/06/2014, 09:20

... http://www.ro-journal.com/content/5 /1/ 16 Page of Table Treatment modalities Parameter No of patients % No 11 73.3 Yes 26. 7 60 13 .3 66 13 .3 70 10 66 .7 72 6. 7 patients forced the use of two-tailed tests to ... advanced head and neck cancer N Engl J Med 2004, 350 :19 45 -19 52 13 Cooper JS, Bernier J: Rationale for triage in the postoperative management of head and neck cancers Oncology 2005, 19 :10 11- 1 017 14 ... End = end of treatment 0% 66 .7% 33.3% 66 .7% 42.9% 0% 33.3% 28 .6% 66 .7% 0% 0% 28 .6% 33.3% 0% 0% Meirovitz et al Radiation Oncology 2 010 , 5: 16 http://www.ro-journal.com/content/5 /1/ 16 Page of Table...

Ngày tải lên: 09/08/2014, 08:22

... 13 CBCT Numbers (HU) 13 79 15 00 19 50 19 90 2000 210 3 215 8 2 468 2500 267 0 3293 3847 Density (g/cm3) 0.0 0.0 0.9 0.9 1. 02 1. 03 1. 06 1. 09 1. 30 1. 50 1 .62 1. 84 1. 86 The densities and CBCT numbers for ... 1Right-eye: mean dose 11 .68 11 . 76 0.70% 1Left-eye: mean dose 10 .54 10 .58 0.37% 1Spinal cord: max dose 47 .65 1. 07% 59 .18 59.44 -0.43% 2GTV: mean dose 67 .8 67 .78 -0.03% 2CTV: mean dose 64 .9 64 .89 -0.02% ... CTV 51. 04 51. 02 32 .14 30.40 50.92 31. 76 55.78 1st kV CBCT 50.23 50.77 50.74 31. 88 30.57 51. 21 31. 17 55 .63 Dose difference between 1st kV CBCT and kV CT(%) 0.98% 0.54% 0.54% 0.8% -0. 56% 0.57% -1. 87%...

Ngày tải lên: 09/08/2014, 08:23